Pressure BioSciences (OTCQB:PBIO) is developing 'must-have' tools in life sciences research as renowned proteomics and genomics experts have published three articles in scientific journals highlighting the advantages of the company's 'pressure cycling technology' (PCT) based instruments and consumables in drug discovery and design, cancer detection, and the analysis of microorganism populations in soil.
In "Use of pressure cycling technology for cell lysis and recovery of bacterial and fungal communities from soil" by Doctors Emily Bruner, Dr. Patricia Okubara & colleagues at Washington State University as well as the USDA-ARS in Pullman WA and Pendleton, OR, published in the April 2015 edition of 'BioTechniques', suggested that PCT may be a valuable alternative to current lysis methods.
The authors compared traditional mechanical lysis methods for direct DNA soil extraction to PBIO's PCT technology suggesting that PCT was more effective. The PCT extracted DNA from a greater number of unique bacterial and fungal species, including microorganisms not found using traditional mechanical lysis methods (greater diversity). The identification of microorganism diversity in soil is critical for successful crop growth and pestilence control according to the research.
In "Structure-relaxation mechanism for the response of T4 lysozyme cavity mutants to hydrostatic Pressure", published in April 2015, the authors of the study at UCLA, Dr. Michael Lerch, Dr. Wayne Hubbell & colleagues from UCLA used PBIO's Barocycler HUB880 and HUB440 instruments and ceramic pressure cells.
The scientists showed that high pressure is emerging as a powerful tool for understanding protein structure and function delivering direct evidence of the different ways proteins can respond to pressure. The study hinted that the way proteins respond to pressure could change the way drugs are designed and developed.
Finally, in an article published last March, in 'Nature Medicine', entitled "Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps," Dr. Tiannan Guo, Dr. Ruedi Aebersold, and colleagues, from ETH Turku Finland, Heidelberg Germany, and St. Gallen Switzerland have indicated that PBIO's PCT-HD, also known as PCT-SWATH, prototype could achieve clinical adoption, expecting it to be used in a wide number of personalized medicine applications.
The authors detected "unprecedented speed and precision" testing a PBIO prototype system based on PCT, the PCT-HD (Barocycler NEP2320 and MicroTubes), showing highly reproducible proteomic analyses of tissue biopsies.
"We are very pleased with the recently published studies from each of these three groups. We consider each a key opinion leading laboratory in their area of focus. We believe their studies show the clear advantages of the PCT platform in testing soil for microbial populations, for expanding our understanding of the complexity of protein structure and function to enable better drug discovery and development, and for developing a new, cutting-edge method to enhance the analysis of tissue biopsies using unprecedented speed and precision," said PBI's Vice President of Marketing and Sales, Dr. Nathan Lawrence.
PBIO can expect the results of the three studies to "lead to additional applications of the PCT Platform", including uses adapting PCT's potential beyond the biological research laboratory to a more profitable clinical laboratory setting.
"It is important to note that all three laboratories used different PCT instruments and consumables. Not only have the results of their studies helped to support the efficacy of the PCT platform in such varied fields of use as agriculture, drug discovery, and cancer detection, but their work has also showcased the enormous breadth of PCT applications, instruments, and consumable products," added Dr. Lawrence.
Indeed, the studies have highlighted both the scientific and commercial potential of PCT technology. In a separate study at Northwestern University, PBIO's Barozyme HT48 was found to have a wide range of epidemiology applications, which could generate growth, increase revenue for existing and new PCT-based applications and products:
"We believe the commercial implications of these three studies, along with the environmental epidemiology applications of the new high throughput Barozyme HT48 System reported recently by Dr. William Funk of Northwestern University, are very large and exciting. Our expanding product portfolio has helped us achieve measurable revenue growth over the past three years. As we begin to significantly add to our sales and marketing capabilities for the first time since 2008, we believe our broad PCT products and applications portfolio will manifest itself in even more significant revenue growth in 2015 and beyond," said PBIO's President and CEO, Richard T. Schumacher.
Pressure BioSciences develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market.
Shares of the company were trading 1.45 percent higher at 0.35 cents on Monday.